Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ADMP is in the long-term down -92% below S&P in 10 years.
Description: Adamis Pharmaceuticals Corporation, a biopharmaceutical company, is engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergies, oncology, and immunology. Its specialty pharmaceutical division has four products in its pipeline, including the Epinephrine Injection Pre-filled Syringe (PFS) for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease (COPD); and APC-3000, a hydrofluoroalkane (HFA) inhaled nasal steroid product for the treatment of allergic rhinitis. The company?s biotechnology division focuses on the development of therapeutic vaccine product candidates and cancer drugs for patients with unmet medical needs in the global cancer markets. Its four products under development include TeloB-VAX, a novel cell-based therapeutic cancer vaccine for prostate cancer; and three drugs comprise APC-100, APC-200, and APC-300 for
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||-1.07||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-4.86|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-80.02%||ROE||-94.54%||ROI|
|Current Ratio||2.58||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.18|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||10.64 M||Cash From Investing Activities||Cash From Operating Activities||-3.17 M||Gross Profit|
|Net Profit||-3.14 M||Operating Profit||-4.15 M||Total Assets||20.01 M||Total Current Assets||11.32 M|
|Total Current Liabilities||2.28 M||Total Debt||Total Liabilities||2.28 M||Total Revenue|
|High 52 week||5.65||Low 52 week||1.84||Last close||1.9||Last change||3.26%|
|RSI||41.67||Average true range||0.12||Beta||0.35||Volume||88.65 K|
|Simple moving average 20 days||-5.24%||Simple moving average 50 days||-11.02%||Simple moving average 200 days||-45.1%|
|Performance Week||-3.06%||Performance Month||-0.52%||Performance Quart||-56.32%||Performance Half||-39.2%|
|Performance Year||-58.7%||Performance Year-to-date||-55.81%||Volatility daily||3.66%||Volatility weekly||8.19%|
|Volatility monthly||16.79%||Volatility yearly||58.16%||Relative Volume||256.82%||Average Volume||388.73 K|
|New High||New Low|
2019-11-12 19:05:12 | Adamis Pharmaceuticals ADMP Reports Q3 Loss, Misses Revenue Estimates
2019-11-07 08:54:01 | Implied Volatility Surging for Adamis Pharmaceuticals ADMP Stock Options
2019-11-01 10:30:02 | Will Adamis Pharmaceuticals ADMP Report Negative Q3 Earnings? What You Should Know
2019-10-08 09:00:00 | Adamis Pharmaceuticals Announces Presentation of ZIMHI data at IHV Scientific Meeting
2019-09-03 09:00:00 | Adamis Pharmaceuticals Provides Update for Naloxone Product Candidate
2019-08-28 09:00:00 | Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI
2019-08-26 16:05:00 | Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
2019-08-14 09:00:00 | Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary
2019-08-09 13:35:56 | Edited Transcript of ADMP earnings conference call or presentation 8-Aug-19 9:00pm GMT
2019-08-08 20:40:12 | Adamis Pharmaceuticals ADMP Reports Q2 Loss, Misses Revenue Estimates
2019-08-01 09:00:00 | Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants
2019-07-31 16:05:00 | Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
2019-07-26 09:13:01 | Will Flagship Impella Drive ABIOMED's ABMD Q1 Earnings?
2019-07-26 09:12:01 | Masimo MASI to Report Q2 Earnings: What's in the Offing?
2019-07-25 07:37:11 | What's in the Offing for DexCom's DXCM Earnings in Q2?
2019-07-24 09:00:00 | Adamis Pharmaceuticals Provides Update on Litigation with Belcher Pharmaceuticals
2019-07-18 13:52:31 | Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
2019-07-09 08:30:00 | Adamis Pharmaceuticals Provides Update on U.S. Retail Launch of SYMJEPI
2019-07-09 07:45:02 | Novartis launches Adamis allergy shots in U.S. pharmacies amid EpiPen shortage
2019-06-27 09:00:00 | Adamis Pharmaceuticals Provides Update on Litigation with kaléo Inc.
2019-06-20 10:02:22 | Have Insiders Been Selling Adamis Pharmaceuticals Corporation NASDAQ:ADMP Shares?
2019-06-11 09:00:00 | Adamis Pharmaceuticals Provides Update on Its Higher Dose Naloxone Injection Product
2019-05-10 14:02:01 | Edited Transcript of ADMP earnings conference call or presentation 9-May-19 9:00pm GMT
2019-05-09 17:55:09 | Adamis Pharmaceuticals ADMP Reports Q1 Loss, Misses Revenue Estimates
2019-05-09 16:51:19 | Adamis: 1Q Earnings Snapshot
2019-03-15 16:39:50 | Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update
2019-03-13 11:51:10 | Before You Buy Adamis Pharmaceuticals Corporation NASDAQ:ADMP, Consider Its Volatility
2019-02-26 18:54:40 | Adamis Provides Regulatory Update on Sublingual Tadalafil